June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Ocular Outcomes of Combination Enzyme Replacement Therapy with Hematopoietic Cell Transplantation in Hurler Syndrome
Author Affiliations & Notes
  • Alejandra Decanini
    Ophthalmology and Visual Neuroscience, University of Minnesota, Minneapolis, MN
  • Julian Tokarev
    Ophthalmology and Visual Neuroscience, University of Minnesota, Minneapolis, MN
  • Julie Eisengart
    Pediatrics, University of Minnesota, Minneapolis, MN
    Neurology, University of Minnesota, Minneapolis, MN
  • Elsa Shapiro
    Pediatrics, University of Minnesota, Minneapolis, MN
    Neurology, University of Minnesota, Minneapolis, MN
  • C Gail Summers
    Ophthalmology and Visual Neuroscience, University of Minnesota, Minneapolis, MN
    Pediatrics, University of Minnesota, Minneapolis, MN
  • Paul Orchard
    Pediatrics, University of Minnesota, Minneapolis, MN
  • Jakub Tolar
    Pediatrics, University of Minnesota, Minneapolis, MN
  • Erick D, Bothun
    Ophthalmology and Visual Neuroscience, University of Minnesota, Minneapolis, MN
    Pediatrics, University of Minnesota, Minneapolis, MN
  • Footnotes
    Commercial Relationships Alejandra Decanini, None; Julian Tokarev, None; Julie Eisengart, None; Elsa Shapiro, None; C Summers, None; Paul Orchard, None; Jakub Tolar, None; Erick Bothun, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5826. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alejandra Decanini, Julian Tokarev, Julie Eisengart, Elsa Shapiro, C Gail Summers, Paul Orchard, Jakub Tolar, Erick D, Bothun; Ocular Outcomes of Combination Enzyme Replacement Therapy with Hematopoietic Cell Transplantation in Hurler Syndrome. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5826.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Although hematopoietic cell transplantation (HCT) is an effective treatment for mucopolysaccharidosis type I (Hurler syndrome, MPS IH), it is unclear whether the additional use of enzyme replacement therapy (ERT) for further systemic improvement affects the ocular outcome. We performed a retrospective, observational clinical study to learn about the ocular outcomes of children receiving ERT before and after HCT for Hurler syndrome, MPS IH, compared to a matched control group receiving only HCT.

Methods: This single institution, retrospective study reviewed the ophthalmologic findings of children with MPS IH who were treated with recombinant a-L iduronidase ERT for 10-14 weeks prior to and 8 weeks following transplantation (combined therapy), compared with an age and transplant matched control group that did not receive ERT. The data collected included age, vision, and ocular examination details.

Results: Nine children in each cohort (ERT with HCT vs. HCT-only) were followed for 61.2 and 61.5 months, respectively. At last follow-up, mean best-corrected visual acuity in the ERT with HCT group was 0.45 logMAR below age-adjusted, normal acuity compared to 0.37 logMAR below age-adjusted normal acuity in the HCT group (p = 0.2650). The children in the combined therapy group performed optotype acuities at earlier ages than those undergoing only HCT (46 vs 73 months, p = 0.0041).

Conclusions: Visual outcomes in children with MPS 1H undergoing HCT do not appear to be better when ERT is given in conjunction with HCT when compared to a matched group receiving HCT alone. Longer follow-up with a large sample of patients may clarify the impact of ERT with HCT combination therapy for MPS IH.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×